Trinity Biotech (TRIB) Non-Current Deferred Tax Liability (2009 - 2025)

Trinity Biotech's Non-Current Deferred Tax Liability history runs 17 years deep, the most recent figure standing at $4.7 million for Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability rose 2.32% year-over-year to $4.7 million; the TTM figure through Dec 2025 stood at $4.7 million (up 2.32% YoY), while the FY2025 annual figure was $4.7 million, up 2.32% from the prior year.
• Non-Current Deferred Tax Liability came in at $4.7 million for Q4 2025 at Trinity Biotech, up from $4.6 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $5.4 million in Q2 2022 to a low of $195000.0 in Q4 2023.
• A 5-year average of $4.0 million and a median of $4.6 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability plunged 96.14% in 2023 and surged 2238.97% in 2024, its largest moves.
• Trinity Biotech's Non-Current Deferred Tax Liability stood at $4.9 million in 2021, then rose by 4.12% to $5.1 million in 2022, then slumped by 96.14% to $195000.0 in 2023, then soared by 2238.97% to $4.6 million in 2024, then gained by 2.32% to $4.7 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $4.7 million, $4.6 million, and $4.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison